Skip to main content

    Candel Therapeutics (CADL) receives Buy upgrade from B of A Securities

    GNG Research Market News

    By GNG Research

    On September 21, 2026, B of A Securities raised its Candel Therapeutics Inc (CADL) rating from Neutral to Buy.

    Among three firms active over the past 90 days, three hold a bullish rating. As of October 30, 2026, 10 analysts place the consensus mean at $23.33, the median at $24.48 and the range at $15.15 to $30.45.

    The Q4 FY2026 consensus calls for -$0.38 in EPS on $0 in revenue. The next earnings date is March 10, 2027.